INOVIQ (IIQ.AX) Stock Price

INOVIQ Price

ASX·CLOSED
0.14
​
Market closed

Revenue at INOVIQ has contracted by 13.4% per year over the past 18 years to 432,047.00 AUD. INOVIQ's net margin stands at -1,737.1%, up from -6,575.0% several years earlier.

INOVIQ stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INOVIQ business model & stock analysis

INOVIQ Ltd, listed on the Australian Securities Exchange under the ticker IIQ.AX, is a health care company operating within the health care sector. The company went public through an IPO on April 18, 1991. INOVIQ provides medical services and has developed two products for market: the hTERT ICC test and the EXO-NET Pan-Exosome. The hTERT ICC test is an immunocytochemistry assay designed for detecting human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to assist in resolving indeterminate cytology results and identifying patients at higher risk for bladder cancer. EXO-NET Pan-Exosome is a research use only (RUO) tool for capturing exosomes from body fluids such as plasma, urine, and saliva. The company is developing blood tests for the early detection and monitoring of various cancers, including ovarian, breast, and prostate cancers. INOVIQ's focus on cancer diagnostics through innovative testing methods positions it within the biotechnology segment of the health care industry. The company's website is www.inoviq.com, and it operates from an undisclosed location within Australia. No additional details regarding the company's founding year, specific leadership, or financial figures are provided in the available information.

Frequently asked questions about INOVIQ

Converted at the current exchange rate, the INOVIQ share trades at 0.08 EUR (0.14 AUD).

The INOVIQ share (IIQ.AX) is listed on 3 stock exchanges, including: ASX (IIQ.AX), Frankfurt (EGQ0.F), München (EGQ0.MU).

The revenue of INOVIQ is 432,047.00 AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of INOVIQ is -7.51 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of INOVIQ is currently -2.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the INOVIQ stock.

The price-to-sales ratio (P/S) of INOVIQ is currently 43.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the INOVIQ stock.

The Eulerpool Quality Score for INOVIQ is 2/10.

The ISIN of INOVIQ is AU0000196149. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of INOVIQ is A3C85Z. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of INOVIQ is IIQ.AX. The ticker symbol is used to trade INOVIQ shares on the stock exchange.

Fair ValueTerminal
0.11 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website inoviq.com
Country
Australia
Currency
AUD
Initial public offering
Apr 18, 1991
ISIN
AU0000196149
Cusip
Q1303D147
Market capitalization
19.01 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-2.08
P/Ee 2028
-2.81
P/Ee 2029
-6.75
P/Ee 2030
0.64
P/Se
10.00
EV/EBIT
—
P/B Ratio
1.01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-39.13 %
Last updated Oct 16, 2026, 6:13 AM

INOVIQ Peer Group

INOVIQ Ticker

ASX · IIQ.AXFRANKFURT · EGQ0.FMUNICH · EGQ0.MU

INOVIQ FIGI

IIQ:AU · BBG000PJHSP3IIQ:AT · BBG000PJHTB6EGQ0:GR · BBG000PXSGR4EGQ0:GF · BBG000PXSJ25EGQ0:GS · BBG000PXSKP7EGQ0:GM · BBG000PXSL48EGQ0:GB · BBG000PXSL93EUG:XT · BBG000QB65Y1EUG:XW · BBG000QB66P9EUG:EU · BBG000QB6919IIQ:AH · BBG002F3K3T2EUG:XV · BBG005919PR2

All fundamentals and in-depth analysis of INOVIQ

Our stock analysis for INOVIQ stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of INOVIQ. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.